WO2016162819A1 - Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha - Google Patents

Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha Download PDF

Info

Publication number
WO2016162819A1
WO2016162819A1 PCT/IB2016/051971 IB2016051971W WO2016162819A1 WO 2016162819 A1 WO2016162819 A1 WO 2016162819A1 IB 2016051971 W IB2016051971 W IB 2016051971W WO 2016162819 A1 WO2016162819 A1 WO 2016162819A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
stable aqueous
aqueous pharmaceutical
composition according
adalimumab
Prior art date
Application number
PCT/IB2016/051971
Other languages
English (en)
Inventor
Paresh VADGAMA
Kedar Gokhale
Rustom Sorab MODY
Deepali SONAWANE
Original Assignee
Lupin Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Limited filed Critical Lupin Limited
Publication of WO2016162819A1 publication Critical patent/WO2016162819A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Definitions

  • the invention provides stable aqueous pharmaceutical compositions of Adalimumab or its biosimilar or its biobetter which is suitable for long term storage. More particularly the suitable stable aqueous pharmaceutical compositions comprising Adalimumab which is free of surfactant or essentially free of surfactant.
  • the invention also provides methods of manufacturing the pharmaceutical composition, method of administration and kits containing the same.
  • Tumor necrosis factor (TNF) alpha is a cytokine that promotes the inflammation and its associated signs by binding to its receptor. It is produced by macrophages and many other immune cells. It is involved in pathogenesis of many inflammatory disorders like rheumatoid arthritis, psoriatic arthritis, SLE, Crohn's disease etc.
  • Hohmann et al Hohmann et al (Hohmann et al. 1989 Biol Chem. 25, 14927-34) identified 2 distinct receptors of TNF-alpha which are present on different cell type's viz. myeloid cells and epithelial cells. Using monoclonal antibodies, Brockhaus et al (Brockhaus et al. 1990 Proc Natl Acad Sci U S A., 87(8), 3127-31) demonstrated that both TNF-alpha and beta bind to both the receptors with high affinity.
  • TNF-alpha Tumor necrosis factor-alpha
  • TNF-alpha antagonists may be effective in treating inflammatory disorders in which TNF-alpha plays an important pathogenic role. Inhibition of TNF has proven to be an effective therapy for patients with rheumatoid arthritis and other forms of inflammatory disease including psoriasis, psoriatic arthritis, and ankylosing spondylitis, inflammatory bowel disease.
  • TNF-alpha antagonist is Adalimumab.
  • Adalimumab is a recombinant human IgGl monoclonal antibody specific for human tumor necrosis factor (TNF). It is produced using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgGl: k constant regions. It is also known as D2E7. Adalimumab has been described in US6090382.
  • Adalimumab interferes with TNF and acts as a TNF inhibitor due to which it can be used as a biopharmaceutical to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, plaque psoriasis, juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis and hidradenitis suppurativa.
  • Adalimumab Dosage of Adalimumab depends on the disease, severity of condition, patient's clinical history, and response to the (prior) therapy, and will be adjusted and monitored by a physician.
  • the pharmaceutical composition may be administered parenterally, such as subcutaneously, intramuscularly, intravenously, intraperitoneally, intracerebrospinally, intraarticularly, intrasynovially and/or intrathecally by either bolus injection or continuous infusion.
  • Adalimumab is available in both single-use prefilled pen and single-use pen in aqueous form.
  • the most important feature of a composition is to help the protein to retain its structural conformation or its activity.
  • the stability of protein in a composition can be related with long-term storage. It is understood to mean that the active polypeptide of the pharmaceutical composition does not substantially lose its activity as compared to the composition at the beginning of storage. All polypeptides have an Isoelectric Point (pi), which is generally defined as the pH at which a polypeptide carries no net charge. It is known in the art that protein solubility is typically lowest when the pH of the solution is equal to the isoelectric point (pi) of the protein.
  • the melting temperature (Tm) of the Fab domain of a protein is a good indicator of the thermal stability of a protein and may further provide an indication of the shelf-life.
  • Tm values of proteins determined by differential scanning calorimetry give insight into heat-induced changes in protein conformation, mechanisms of protein unfolding and stabilization in solution. A lower Tm indicates less stability of a protein in the given solution, whereas a higher Tm indicates a better stability of the protein.
  • the Tm of the protein will vary based on the formulation composition which in turn reflects its stability in respective formulation.
  • aqueous composition of proteins can lose active protein due to aggregation or degradation. Aggregation of the protein can lead to immunogenicity and is undesirable. Since the high concentration of Adalimumab used in the composition therefore, there is a likely possibility of protein aggregation during long term storage. To improve the stability of the protein either the concentration of the existing excipients can be varied or new excipients can be added to modify the composition.
  • Surfactant is extensively used and also considered as a most desirable choice to skilled person in order to maintain the stability or prevent aggregation of protein molecule.
  • the invention is related to a stable aqueous pharmaceutical composition comprising Adalimumab, buffer system and said composition is free or essentially free of surfactant.
  • the invention is related to a stable aqueous pharmaceutical composition comprising Adalimumab, buffer system, a tonicity agent, stabilizer and optionally an anti-aggregating agent wherein the said composition is free or essentially free of surfactant.
  • the present invention provides a stable aqueous pharmaceutical composition of Adalimumab free of surfactant or essentially free of surfactant which exhibits a long term stability.
  • the present invention provides a stable aqueous pharmaceutical composition buffered between pH 4 to 8.
  • the composition may further by lyophilized.
  • the invention is related to a stable aqueous pharmaceutical composition of Adalimumab free or essentially free of a surfactant comprising a buffer system selected from histidine, succinate, phosphate, citrate, acetate, maleate and tartrate buffers or combination thereof; tonicity agent is selected from sodium chloride or potassium chloride; stabilizer is selected from one or more polyols, sugars, cyclodextrins and optionally other excipients selected from stabilizers or anti-aggregating agents such as amino acids and having pH 4 to 8.
  • a buffer system selected from histidine, succinate, phosphate, citrate, acetate, maleate and tartrate buffers or combination thereof
  • tonicity agent is selected from sodium chloride or potassium chloride
  • stabilizer is selected from one or more polyols, sugars, cyclodextrins and optionally other excipients selected from stabilizers or anti-aggregating agents such as amino acids and having pH 4 to 8.
  • the stable aqueous pharmaceutical composition comprising Adahmumab in the concentration of more than 45 mg/ml and preferably about 45 mg/ml to about 160 mg/ml of Adahmumab; buffer system comprises about 1 mM to about 50 mM of sodium dihydrogen phosphate dihydrate, about 0.1 mM to about 50 mM of disodium hydrogen phosphate dihydrate, about 0.1 mM to about 50 mM of trisodium citrate dihydrate, about 1 mM to about 100 mM of citric acid monohydrate; about 10 mM to about 300 mM of sodium chloride; about 10 mM to about 100 mM of mannitol; about 5 mM to about 100 mM of L-arginine monohydrochloride and having pH 5.2 ⁇ 0.3.
  • the stable aqueous pharmaceutical composition comprising Adahmumab in the concentration of more than 45 mg/ml and preferably about 45 mg/ml to about 160 mg/ml of Adahmumab; buffer system comprises about 1 mM to about 50 mM of sodium dihydrogen phosphate dihydrate, about 0.1 mM to about 50 mM of disodium hydrogen phosphate dihydrate, about 0.1 mM to about 50 mM of trisodium citrate dihydrate, about 1 mM to about 100 mM of citric acid monohydrate; about 10 mM to about 300 mM of sodium chloride; about 10 mM to about 100 mM of mannitol; about 5 mM to about 100 mM of glycine and having pH 5.2 ⁇ 0.3.
  • the invention is related to the method of treating a disease using the stable aqueous pharmaceutical composition of the present invention wherein the disease is selected from rheumatoid arthritis, psoriatic arthritis, Crohn's disease, plaque psoriasis, juvenile idiopathic arthritis, active ankylosing spondylitis, ulcerative colitis and hidradenitis suppurativa.
  • the invention is related to a kit or a container containing the pharmaceutical composition of the invention.
  • surfactant refers to an excipient which inhibits the aggregation of Adalimumab.
  • the example of surfactant comprises but not limited to polysorbate 20, polysorbate 80, Brij 35, Triton X-10, Pluronic F127, and sodium doceyl Sulfate (SDS) and Pluronic F68 (poloxamer 188)
  • the term “without” or “free” refers to a composition contains less than 0.1 mM surfactant or less than 0.01 mM or less than 0.0001 mM surfactant.
  • the term “without” or “free” are interchangeable.
  • essentially free means that either no surfactant is present or only minimal, trace amounts of the surfactant is present which do not have any substantial impact on the properties of the composition. If reference is made to no amount of a surfactant, it should be understood as "no detectable amount”.
  • buffer system refers to a buffered solution that resists changes in pH by the action of its acid-base conjugate components.
  • suitable buffers system includes but are not limited to phosphate buffers, citrate-buffers, histidine -buffers, succinate-buffers, acetate -buffers, tartrate buffers, tromethamine buffers and the combinations thereof.
  • long-term storage or “long term stability” is understood to mean that the pharmaceutical composition can be stored for three months or more, for six months or more, and preferably for one year or more, most preferably a minimum stable shelf life of at least two years.
  • long term storage and “long term stability” further include stable storage durations that are at least comparable to or better than the stable shelf typically required for currently available commercial formulations of Adalimumab, without losses in stability that would render the formulation unsuitable for its intended pharmaceutical application.
  • Long-term storage is also understood to mean that the pharmaceutical composition is stored either as a liquid at 2-8° C, or is frozen, e.g., at -20° C, or colder. It is also contemplated that the composition can be frozen and thawed more than once.
  • stable with respect to long-term storage is understood to mean that Adalimumab contained in the pharmaceutical compositions does not lose more than 20%, or more preferably 15%, or even more preferably 10%, and most preferably 5% of its activity of the composition at the beginning of storage.
  • the invention provides an improved stable aqueous pharmaceutical composition of Adalimumab free or essentially free of a surfactant. More particularly, the invention relates to the stable aqueous pharmaceutical composition of Adalimumab free or essentially free of a surfactant comprising a buffer system, a tonicity agent and a stabilizer and optionally other excipients selected from stabilizers or anti-aggregating agents which exhibits a lower degradation potential.
  • an improved stable aqueous pharmaceutical composition of Adalimumab comprising a buffer system, a tonicity agent and a stabilizer and optionally other excipients which can be lyophilized wherein the composition is free of surfactant or essentially free of surfactant.
  • the stable aqueous pharmaceutical composition comprises a buffer system which plays critical role to regulate the stability of formulation and therefore selection of suitable buffer system is highly desirable to obtain the surfactant free stable formulation.
  • the buffer system is selected from phosphate buffers, citrate -buffers, histidine -buffers, succinate - buffers, acetate -buffers, tartrate buffers, tromethamine buffers and the combinations thereof.
  • the suitable buffer system comprises of a phosphate buffer.
  • the suitable buffer system comprises a phosphate-citrate buffer.
  • the pharmaceutical composition comprises; Adalimumab; buffer system comprises the combination of phosphate and citrate buffer selected from the group essentially consisting of sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dihydrate, trisodium citrate dihydrate, citric acid monohydrate.
  • the stable aqueous pharmaceutical composition comprises tonicity agent(s) selected from sodium chloride or potassium chloride. In preferred embodiment the tonicity agent is sodium chloride.
  • the stable aqueous pharmaceutical composition comprises one or more suitable stabilizers.
  • the suitable stabilizer is selected from polyols, sugars, cyclodextrins and the combinations thereof.
  • polyols selected from mannitol, sorbitol, dextran, glycerol, arabitol, propylene glycol, polyethylene glycol and suitable combinations thereof.
  • suitable polyol is mannitol.
  • the sugar is a monosaccharide or an oligosaccharide.
  • Monosaccharide sugars are selected from glucose, fructose, galactose, mannose, sorbose, ribose, deoxyribose and the like or amino sugars, like neuraminic acid and suitable combinations thereof.
  • An oligosaccharide is selected from sucrose, trehalose, lactose, maltose and raffinose and suitable combinations thereof.
  • cyclodextrins or derivative thereof are selected from to a- cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin and suitable combinations thereof.
  • the stable aqueous pharmaceutical composition comprises optionally other excipients selected from stabilizers or anti-aggregating agents.
  • other excipients includes but not limited to amino acids which can be used as stabilizers or anti-aggregating agents.
  • the amino acid is selected from arginine, glycine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophane, methionine, serine, proline, cysteine/cystine and suitable combination thereof.
  • the amino acid is arginine.
  • amino acid is arginine monohydrochloride.
  • the amino acid is glycine.
  • the stable aqueous pharmaceutical composition comprises pH value ranging from 4.0 to about 8.0.
  • the pH of formulation is maintained in the range of about 4.9 to 5.5. In a more preferred embodiment the pH is maintained to about 5.2.
  • the stable aqueous pharmaceutical composition comprises Adalimumab generally present in a therapeutic amount of up to 160 mg/mL.
  • the therapeutic amount is about 1 mg/mL to about 100 mg/mL.
  • the therapeutic amount is about 1 mg/mL to about 50 mg/mL.
  • the stable aqueous pharmaceutical composition comprises suitable buffer system generally present in an amount of up to lOOmM. In a preferred embodiment the amount is about lmM to about 50 mM. In a more preferred embodiment the amount is about 15 mM to about 25 mM.
  • the stable aqueous pharmaceutical composition comprises suitable tonicity agent generally present in an amount below 500mM. In a preferred embodiment the amount is about 30mM to about 150mM. In a more preferred embodiment the amount is about 60mM to about 120mM.
  • the stable aqueous pharmaceutical composition comprises suitable stabilizer generally present in an amount below 500mM. In a preferred embodiment the amount is about lmM to about 200mM. In a more preferred embodiment the amount is about lOmM to about lOOmM.
  • the stable aqueous pharmaceutical composition comprises suitable stabilizer or anti-aggregating agent in an amount below 500 mM.
  • the amount is about lmM to about lOOmM.
  • the amount is about lOmM to about 50mM.
  • stable aqueous pharmaceutical composition comprises free or essentially free of surfactant comprises 5 mg/mL to 160 mg/mL of Adalimumab, about 1 mM to 100 mM of phosphate and/or citrate buffer, 5 mM to 500 mM of sodium chloride and 5 mM to 500 mM mannitol and optionally lmM to about lOOmM L-arginine monohydrochloride or glycine and having a pH range of 4 to 8.
  • stable aqueous pharmaceutical composition comprises free or essentially free of surfactant comprises 5 mg/mL to 160 mg/mL of Adalimumab, about 1 mM to 100 mM of phosphate and 1 mM to 100 mM citrate buffer, 5 mM to 500 mM of sodium chloride and 5 mM to 500 mM mannitol, and optionally lmM to about lOOmM L-arginine monohydrochloride or glycine and having a pH range of 4 to 8.
  • stable aqueous pharmaceutical composition comprises free or essentially free of surfactant comprises 5 mg/mL to 160 mg/mL of Adalimumab, about 1 mM to 100 mM phosphate buffer, 5 mM to 500 mM of sodium chloride and 5 mM to 500 mM mannitol, and optionally ImM to about lOOmM L-arginine monohydrochloride or glycine and having a pH range of 4 to 8.
  • stable aqueous pharmaceutical composition comprises free or essentially free of surfactant comprises 5 mg/mL to 160 mg/mL of Adalimumab, about 1 mM to 100 mM citrate buffer, 5 mM to 500 mM of sodium chloride and 5 mM to 500 mM mannitol, and optionally ImM to about lOOmM L-arginine monohydrochloride or glycine and having a pH range of 4 to 8.
  • stable aqueous pharmaceutical composition comprises free or essentially free of surfactant comprises 5 mg/mL to 160 mg/mL of Adalimumab, about 1 mM to 100 mM of phosphate and/or citrate buffer, 5 mM to 500 mM of sodium chloride, 5 mM to 500 mM mannitol and 5 mM to 100 mM of L-arginine monohydrochloride and having a pH range of 4 to 8.
  • stable aqueous pharmaceutical composition comprises free or essentially free of surfactant comprises 5 mg/ml to 160 mg/mL of Adalimumab, about 1 mM to 100 mM of phosphate and/or citrate buffer, 5 mM to 500 mM of sodium chloride, 5 mM to 500 mM mannitol and 5 mM to 100 mM of glycine and having a pH range of 4 to 8.
  • the present invention found that use of buffer system with at least more than one buffer like phosphate and citrate buffer in suitable concentration significantly reduced or completely eliminated the requirement of surfactant and provides long term stable Adalimumab composition.
  • the invention further describes the use of sodium chloride as a tonicity agent, polyol as a stabilizing agent and optionally arginine or glycine as other excipients in combination with phosphate and citrate buffer to provide lone term stability in absence of surfactant.
  • the stable aqueous pharmaceutical composition exhibiting a long term stability and free or essentially free of surfactant
  • Adalimumab comprising; Adalimumab; buffer system comprises the combination of phosphate and citrate buffer selected from the group essentially consisting of sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dihydrate, trisodium citrate dihydrate, citric acid monohydrate; sodium chloride; mannitol; optionally anti-aggregating agent is L-arginine monohydrochloride and having pH 5.2 ⁇ 0.3.
  • buffer system comprises about 1 mM to about 50mM of sodium dihydrogen phosphate dihydrate about 0.1 mM to about 50 mM of disodium hydrogen phosphate dihydrate about 0.1 mM to about 50 mM of trisodium citrate dihydrate, about 1 mM to about 100 mM of citric acid monohydrate and having pH 5.2 ⁇ 0.3;
  • buffer system comprises about 1 mM to about 50 mM of sodium dihydrogen phosphate dihydrate, about 0.1 mM to about 50 mM of disodium hydrogen phosphate dihydrate, about 0.1 mM to about 50 mM of trisodium citrate dihydrate, about 1 mM to about 100 mM of citric acid monohydrate;
  • the stable aqueous pharmaceutical composition comprising:
  • buffer system comprises 5.5 mM of sodium dihydrogen phosphate dihydrate, 8.6 mM of disodium hydrogen phosphate dihydrate, 1 mM of trisodium citrate dihydrate, 6.2 mM of citric acid monohydrate;
  • buffer system comprises 5. 5 mM of sodium dihydrogen phosphate dihydrate, 8.6 mM of disodium hydrogen phosphate dihydrate, 1 mM of trisodium citrate dihydrate, 6.2 mM of citric acid monohydrate;
  • the invention provides pharmaceutical composition essentially comprising of Adalimumab free or essentially free of surfactant.
  • the pharmaceutical composition is a sterile and stable for long period of time at 2-8 C. In certain embodiment the pharmaceutical composition is a sterile and stable for long period of time at 25 C. In certain embodiment the pharmaceutical composition is a sterile and stable for long period of time at 40 C. In certain embodiments the pharmaceutical composition is stable at non-refrigerated temperature for extended period of time. In certain embodiment pH of the formulation is maintained about 5.2 ⁇ 0.3 for at least 15 days, preferably one month, more preferably 3 months most preferably six months to two years.
  • formulation comprises impurities below 10% or preferably below 5% or more preferably below 1% for at least 15 days, preferably one month, more preferably 3 months and most preferably six months to two years.
  • formulation comprises acidic variant below 25% or preferably below 15% or more preferably below 10% for at least 15 days, preferably one month, more preferably 3 months and most preferably six months to two years. In certain embodiment formulation maintains purity at least 75% or preferably more than 85% for at least 15 days, preferably one month, more preferably 3 months and most preferably six months to two years.
  • the invention in another embodiment, relates to a kit comprising Adalimumab; buffer system comprises the combination of phosphate and citrate buffer selected from the group essentially consisting of sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dihydrate, trisodium citrate dihydrate, citric acid monohydrate and having pH 5.2 ⁇ 0.3; sodium chloride; mannitol; optionally anti-aggregating agent is L-arginine monohydrochloride.and instructions for use of the present composition.
  • buffer system comprises the combination of phosphate and citrate buffer selected from the group essentially consisting of sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dihydrate, trisodium citrate dihydrate, citric acid monohydrate and having pH 5.2 ⁇ 0.3
  • sodium chloride mannitol
  • optionally anti-aggregating agent is L-arginine monohydrochloride.and instructions for use of the present composition.
  • the composition is contained in a pre-filled syringe. In a further preferred embodiment, the composition is contained in a pre-filled vial. In Another preferred embodiment is a pre-filled syringe within an autoinjector.
  • the kit may comprise one or more unit dosage forms containing the pharmaceutical composition of the invention.
  • the kit may also comprise of the pharmaceutical composition according to the invention in another secondary container, such as in an autoinjector.
  • the prefilled syringe may contain the composition in aqueous form. Described syringe may be further supplied with an autoinjector or pen, which often is a disposable article for single use only, and may have a volume between 0.1 and 1 mL.
  • the described vial may contain the composition in lyophilised or aqueous state, and may serve as a single or multiple use devices.
  • the vial may have a volume between 1 and 10 mL.
  • the invention further relates to a stable pharmaceutical composition, wherein the composition is liquid or lyophilized.
  • the invention is further related to a stable pharmaceutical composition in a pre-filled syringe, vial or cartridge.
  • the method may further comprise a lyophilization step, which may be before or after adding the at least one tonicity modifier, and/or an excipient as defined above.
  • Adalimumab which was used in the described examples of the present invention, is produced from CHO cells by using recombinant DNA technology method which is well known in the general art.
  • the CHO cells were cultured in a fed-batch process known in the art.
  • Adalimumab was purified from the cell free harvest by standard purification and filtration process known in the art including affinity chromatography and further chromatographic and filtration steps.
  • Example 1 Process for Preparation of stable pharmaceutical composition of
  • Adalimumab The drug substance of purified Adalimumab is obtained and formulated by using various excipients in the present example which is shown in Table 1.
  • the concentration of 50 mg/ml Adalimumab is formulated with excipients in absence of polysorbate 80.
  • Only phosphate buffer is used in Formulation 2 along with other excipients sodium chloride, mannitol at pH of 5.2 ⁇ 0.3 adjusted by 2M sodium hydroxide as mentioned in Table 1 and two buffers phosphate and citrate buffer are used in formulation 1 with other excipients sodium chloride, mannitol at pH of 5.2 ⁇ 0.3 adjusted by 2M sodium hydroxide.
  • Both formulation 1 and formulation 2 lack surfactant polysorbate 80.
  • Disodium hydrogen phosphate 1.53 mg/mL 0.037 mg/mL
  • Trisodium citrate dihydrate 0.30 mg/mL -
  • Citric acid monohydrate 1.30 mg/mL -
  • Adalimumab The drug substance of purified Adalimumab is obtained and formulated by using various excipients in the present example which is shown in Table 2.
  • the concentration of 50 mg/mL Adalimumab is formulated with excipients in absence of polysorbate80.
  • Only phosphate buffer is used in Formulation 4 along with other excipients sodium chloride, mannitol, L-Arginine HC1 at pH5.2 ⁇ 0.3 adjusted by 2M sodium hydroxide as mentioned in Table 2 and two buffers phosphate and citrate buffer are used in formulation 3 with other excipients sodium chloride, mannitol, L-Arginine HC1 at pH of 5.2 ⁇ 0.3 adjusted by 2M sodium hydroxide.
  • Both formulation 3 and formulation 4 lack surfactant polysorbate 80.
  • Adalimumab The drug substance of purified Adalimumab is obtained and formulated by using various excipients in the present example which is shown in Table 3.
  • Adalimumab The concentration of 50 mg/mL Adalimumab is formulated with excipients in absence of polysorbate 80.
  • Citric acid monohydrate 1.30 mg/mL
  • Adalimumab The formulations of Adalimumab remain stable after 14 days of storage at 25 °C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques aqueuses stables d'Adalimumab, ou de son biosimilaire ou de son biobetter. Elle concerne plus particulièrement des compositions pharmaceutiques aqueuses stables d'Adalimumab pratiquement exemptes de surfactant. L'invention concerne également des procédés de fabrication de la composition pharmaceutique, un procédé d'administration, ainsi que des kits les contenant.
PCT/IB2016/051971 2015-04-07 2016-04-07 Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha WO2016162819A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1460MU2015 2015-04-07
IN1460/MUM/2015 2015-04-07

Publications (1)

Publication Number Publication Date
WO2016162819A1 true WO2016162819A1 (fr) 2016-10-13

Family

ID=55969180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/051971 WO2016162819A1 (fr) 2015-04-07 2016-04-07 Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha

Country Status (1)

Country Link
WO (1) WO2016162819A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (fr) * 2016-12-21 2018-06-28 Amgen Inc. Formulations d'anticorps anti-tnf alpha
WO2018184692A1 (fr) * 2017-04-07 2018-10-11 Ares Trading S.A. Composition pharmaceutique liquide
RU2756619C2 (ru) * 2017-03-16 2021-10-04 ЭлДжи КЕМ, ЛТД. Жидкая композиция антитела против TNF альфа
US11534402B2 (en) 2017-03-06 2022-12-27 Arecor Limited Liquid pharmaceutical composition
US11534403B2 (en) 2017-03-06 2022-12-27 Arecor Limited Liquid pharmaceutical composition
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2116192A1 (fr) * 1993-02-23 1994-08-24 Hitoshi Hayasaka Preparations pharmaceutiques de tcf a concentration elevee
EP0787497A2 (fr) * 1996-02-02 1997-08-06 MITSUI TOATSU CHEMICALS, Inc. Préparation pharmaceutique contenant l'hormone de croissance humaine
US5919757A (en) * 1992-12-18 1999-07-06 Boehringer Mannheim Gmbh Aqueous pharmaceutical preparations of G-CSF with a long shelf life
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
WO2004016286A2 (fr) 2002-08-16 2004-02-26 Abbott Biotechnology Ltd. Formulation d'anti-corps humains pour le traitement de troubles lies au facteur de necrose tumorale alpha
WO2012042371A2 (fr) * 2010-09-30 2012-04-05 Ferring B.V. Composition pharmaceutique
WO2013164837A1 (fr) 2012-03-07 2013-11-07 Cadila Healthcare Limited Formulations pharmaceutiques d'anticorps anti-tnf-alpha
WO2014039903A2 (fr) 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Formulations aqueuses stables d'adalimumab
WO2014099636A1 (fr) 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Formulations liquides pour un anticorps anti-tnfalpha

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919757A (en) * 1992-12-18 1999-07-06 Boehringer Mannheim Gmbh Aqueous pharmaceutical preparations of G-CSF with a long shelf life
CA2116192A1 (fr) * 1993-02-23 1994-08-24 Hitoshi Hayasaka Preparations pharmaceutiques de tcf a concentration elevee
EP0787497A2 (fr) * 1996-02-02 1997-08-06 MITSUI TOATSU CHEMICALS, Inc. Préparation pharmaceutique contenant l'hormone de croissance humaine
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8916158B2 (en) 2002-08-16 2014-12-23 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US8216583B2 (en) 2002-08-16 2012-07-10 Abbott Biotechnology, Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US8802100B2 (en) 2002-08-16 2014-08-12 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-alpha associated disorders
US8911741B2 (en) 2002-08-16 2014-12-16 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-alpha associated disorders
WO2004016286A2 (fr) 2002-08-16 2004-02-26 Abbott Biotechnology Ltd. Formulation d'anti-corps humains pour le traitement de troubles lies au facteur de necrose tumorale alpha
US8916157B2 (en) 2002-08-16 2014-12-23 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
US8932591B2 (en) 2002-08-16 2015-01-13 Abbvie Biotechnology Ltd. Formulation of human antibodies for treating TNF-α associated disorders
WO2012042371A2 (fr) * 2010-09-30 2012-04-05 Ferring B.V. Composition pharmaceutique
WO2013164837A1 (fr) 2012-03-07 2013-11-07 Cadila Healthcare Limited Formulations pharmaceutiques d'anticorps anti-tnf-alpha
WO2014039903A2 (fr) 2012-09-07 2014-03-13 Coherus Biosciences, Inc. Formulations aqueuses stables d'adalimumab
US20150191538A1 (en) 2012-09-07 2015-07-09 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
WO2014099636A1 (fr) 2012-12-18 2014-06-26 Merck Sharp & Dohme Corp. Formulations liquides pour un anticorps anti-tnfalpha

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROCKHAUS ET AL., PROC NATL ACAD SCI USA., vol. 87, no. 8, 1990, pages 3127 - 31
HOHMANN ET AL., J BIOL CHEM., vol. 25, 1989, pages 14927 - 34

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (fr) * 2016-12-21 2018-06-28 Amgen Inc. Formulations d'anticorps anti-tnf alpha
EP3824906A1 (fr) * 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
US11534402B2 (en) 2017-03-06 2022-12-27 Arecor Limited Liquid pharmaceutical composition
US11534403B2 (en) 2017-03-06 2022-12-27 Arecor Limited Liquid pharmaceutical composition
RU2756619C2 (ru) * 2017-03-16 2021-10-04 ЭлДжи КЕМ, ЛТД. Жидкая композиция антитела против TNF альфа
WO2018184692A1 (fr) * 2017-04-07 2018-10-11 Ares Trading S.A. Composition pharmaceutique liquide
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions

Similar Documents

Publication Publication Date Title
US10772960B2 (en) Stable aqueous formulations of adalimumab
WO2016162819A1 (fr) Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha
JP2023109938A (ja) 抗体製剤
US9453067B2 (en) Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
CN106061468B (zh) 包含TNFR和Fc区的融合蛋白的液体制剂
US10058589B2 (en) Stable pharmaceutical composition of Etanercept in a phosphate citrate buffer with glycine as an anti-aggregating agent
EP3143047B1 (fr) Formulation de belimumab
US20200405864A1 (en) Liquid pharmaceutical composition of adalimumab
CA2866692A1 (fr) Formulations empechant la formation d'agregats d'anticorps
JP7402195B2 (ja) 医薬製剤及びその製造方法
JP2024059878A (ja) 高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比
US20240182554A1 (en) Protein solution formulation containing high concentration of an anti-vegf antibody
JP6480154B2 (ja) エタネルセプトの凍結乾燥製剤
EP3563867A1 (fr) Composition pharmaceutique aqueuse d'un anticorps monoclonal recombinant pour le facteur de nécrose tumorale (tnf)
US10959939B2 (en) Liquid pharmaceutical composition of etanercept with lysine and proline
RU2665966C2 (ru) Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
WO2021234584A1 (fr) Compositions pharmaceutiques comprenant de l'adalimumab
JP2022546400A (ja) 高濃度の薬理学的に活性な抗体の新規製剤
WO2019087108A1 (fr) Formulation pharmaceutique stable d'une protéine hybride
JP2018527343A (ja) 改善された安定性を有するエタネルセプト組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16722702

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16722702

Country of ref document: EP

Kind code of ref document: A1